Nizar J. Bahlis
Researcher Next ID · RN-033081
Researcher · Biochemistry, Genetics and Molecular Biology
Calgary, Canada
- Works count
- 794
- Citation count
- 25,068
- H-index
- 72
- i10-index
- 266
Research interests
Publications
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Journal of Clinical Oncology · 2025 · https://doi.org/10.1200/jco-24-01893
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02491-5
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2213614
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02528-9
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203478
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30756-7
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00466-6
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Blood Advances · 2020 · https://doi.org/10.1182/bloodadvances.2020002827
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30110-3
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1817249
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Haematologica · 2018 · https://doi.org/10.3324/haematol.2018.194282
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Blood · 2017 · https://doi.org/10.1182/blood-2017-07-795047
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(15)01120-4
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1607751
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1516282
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1402551
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
Blood · 2013 · https://doi.org/10.1182/blood-2012-09-451872
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
Blood · 2012 · https://doi.org/10.1182/blood-2012-05-425934
Current projects
No projects listed.